Highest-materiality recent filing
Waters shareholders re-elect all 11 directors, ratify PwC, approve say-on-pay at annual meeting
Approx. 90.7M shares (92.4% of eligible) voted at May 21, 2026 annual meeting.
Waters Q1 revenue $1.267B beats guidance; raises FY2026 adjusted EPS outlook to $14.40-$14.60
Total reported revenue of $1.267B exceeded guidance by $56M; GAAP EPS ($0.87) due to acquisition charges, Adjusted EPS $2.70 (+20% YoY).
Waters subsidiary issues $3.5B in senior notes across five tranches to repay DDTL
Issuer Augusta SpinCo completed offering of $3.5B senior notes: 4.321% due 2027, 4.398% 2029, 4.656% 2031, 4.945% 2033, 5.245% 2036.
Waters provides financials for acquired BD Biosciences & Diagnostic Solutions; Q1 rev $766M
Acquisition closed Feb 9, 2026 via Reverse Morris Trust; Waters paid $4B cash distribution to BD.
Q4 sales $932M (+7% reported, +6% CC); GAAP EPS $3.77, non-GAAP EPS $4.53 (+10% YoY).
Waters completes $4B combination with BD's Biosciences & Diagnostic Solutions; forms four divisions
Consummated spin-off and merger of BD's Biosciences & Diagnostic Solutions; BD shareholders received ~0.135 Waters shares per BD share, owning 39.2% of combined company.
Waters shareholders approve BD Biosciences combination; close expected Feb 9, 2026
Approximately 99% of shares present at special meeting voted to approve share issuance for BD Biosciences deal.
Waters supplements merger proxy after two stockholder lawsuits alleging omissions
Two lawsuits filed in NY Supreme Court (Carroll, Clark) claim proxy omits material information; demand letters also received.
Waters furnishes investor presentation at J.P. Morgan Conference; no financial details in excerpt
Filing furnishes investor presentation dated January 12, 2026 for J.P. Morgan Healthcare Conference.
Waters Q3 sales $800M (+8% YoY), non-GAAP EPS $3.40 (+16%), raises FY guidance
Sales $800M, +8% as reported and constant currency, above guidance.
Waters Q2 sales $771M (+9% reported, +8% CC); GAAP EPS $2.47, non-GAAP $2.95; raises FY guidance
Sales $771M, up 9% reported and 8% constant currency vs $709M prior year.
Waters to combine with BD's Biosciences & Diagnostic Solutions in $17.5B deal
Deal valued at ~$17.5B; Waters shareholders own ~60.8%, BD shareholders ~39.2% of combined co.
Waters to acquire BD's Biosciences & Diagnostic Solutions via Reverse Morris Trust
Waters shareholders to own ~60.8% and former SpinCo shareholders ~39.2% of combined company post-merger.
Waters Corp amends credit facility; removes $200M term loan, retains $1.8B revolver through 2030
Removed existing $200M term loan; retained $1.8B senior unsecured revolving credit facility maturing May 22, 2030.
Waters Corp annual meeting elects all 10 directors, approves compensation and ESPP amendment
Approximately 94.12% of shares represented; all 10 director nominees re-elected.
Waters Q1 2025 results announced; financial details not disclosed in excerpt
Quarter ended March 29, 2025 results released May 6, 2025.
Waters Q4 sales $873M beat guidance; non-GAAP EPS $4.10 up 13% YoY; FY2025 EPS guide $12.70-$13.00
Q4 sales $873M, +6% reported / +8% constant currency; exceeded high-end of guidance range.
Waters to present at J.P. Morgan Healthcare Conference on Jan 13, 2025
CEO Udit Batra will present at the J.P. Morgan 43rd Annual Healthcare Conference on January 13, 2025.
Waters appoints Heather Knight to Nominating and Corporate Governance Committee
Heather Knight was appointed to the Board effective August 14, 2024 per prior 8-K.
Waters Q3 sales $740M (+4% YoY); GAAP EPS $2.71, non-GAAP $2.93; raises FY guidance
Sales $740M (+4% as reported and constant currency); GAAP EPS $2.71, non-GAAP EPS $2.93, beating guidance.
Waters Corporation appoints Heather Knight to Board of Directors
Appointed Heather Knight effective Aug 14, 2024; Board size increased from 9 to 10.
Waters reports Q2 2024 results; full financial details unavailable from excerpt
Press release announces results for the quarter ended June 29, 2024, but full text is not provided.
Waters Corp enters $200M private shelf note facility with NYL Investors
Up to $200M senior promissory notes; maturity up to 15 years per issuance.
Quorum of 54.3M shares (91.63%) present; all 9 director nominees elected with votes ranging from 41.8M to 52.4M for.
Waters Corp reports Q1 2024 results; press release text truncated, no specifics available
Company announced Q1 2024 results on May 7, 2024, but the attached press release text is incomplete.
Waters Q4 2023 sales $819M (-4.5%); FY guidance organic growth -0.5% to +1.5%
Q4 GAAP EPS $3.65, non-GAAP $3.62 (at high end of guidance); YoY decline from $3.84.
On August 13, 2024, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Heather Knight to the Board, effective August 14, 2024, to fill the vacancy so created.
Max materiality 0.90 · Median 0.65 · Most common event earnings